{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:10:51Z","timestamp":1793988651217,"version":"4.8.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Coexisting anti-NMDAR and MOG antibody (anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup>)-associated encephalitis have garnered great attention. This study aimed to perform a secondary analysis to determine the clinical features of this disease. We searched several databases for related publications published prior to April 2021. A pooled analysis was conducted with the fixed-effects model using the Mante-Haenszel method (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> \u2264 50%), or the random-effects model computed by the DerSimonian\u2013Laird method (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> &amp;gt; 50%). Stata software (version 15.0 SE) was used for the analyses. Nine observational studies and 16 case reports (58 cases with anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup>, 21.0 [8.5, 29.0] years, male 58.6%) were included. The incidences (95%CI) of anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup> in the patients with serum MOG-IgG<jats:sup>+<\/jats:sup> and CSF anti-NMDAR-IgG<jats:sup>+<\/jats:sup> were 0.09 (0.02\u20130.19) and 0.07 (0.01\u20130.19), respectively. The median [IQR] of CSF anti-NMDAR antibody titer was 32 [10, 100], and the serum anti-MOG antibody titer was 100 [32, 320]. The prominent clinical symptoms were encephalitic manifestations, including seizures (56.9%) and abnormal behavior (51.7%), rather than demyelinating manifestations, such as speech disorder (34.5%) and optic neuritis (27.6%). Relapse occurred in 63.4% of anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup> patients, in whom 50.0% of cases relapsed with encephalitic manifestations, and 53.8% relapsed with demyelinating manifestations. The common MRI changes were in the cortex or subcortex (70.7%) and brainstem (31.0%). 31.3% of patients presented with unilateral cerebral cortical encephalitis with epilepsy and 12.5% displayed bilateral frontal cerebral cortex encephalitis. Anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup> patients showed more frequent mental behavior (OR, 95%CI, 68.38, 1.36\u20133,434.37), involuntary movement (57.86, 2.53\u20131,325.11), sleep disorders (195.00, 7.07\u20135,380.15), and leptomeninge lesions (7.32, 1.81\u201329.58), and less frequent optic neuritis (0.27, 0.09\u20130.83) compared to anti-NMDAR-IgG<jats:sup>\u2212<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup> patients and presented more common relapse (5.63, 1.75\u201318.09), preceding infection (2.69, 1.03\u20137.02), subcortical lesions (116.60, 4.89\u20132,782.09), basal ganglia lesions (68.14, 2.99\u20131,554.27), brainstem lesions (24.09, 1.01\u2013574.81), and spinal cord lesions (24.09, 1.01\u2013574.81) compared to anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>\u2212<\/jats:sup>. In conclusion, anti-NMDAR-IgG<jats:sup>+<\/jats:sup>\/MOG-IgG<jats:sup>+<\/jats:sup> was rarely observed, but the incidence rate of relapse was very high. The overall symptoms seemed to be similar to those of NMDAR encephalitis.<\/jats:p>","DOI":"10.3389\/fneur.2021.711376","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T21:19:52Z","timestamp":1630099192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiayue","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yebeh.2016.12.019","article-title":"Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: a systematic review of reported cases","volume":"68","author":"Zhang","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1212\/NXI.0000000000000731","article-title":"Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies","volume":"7","author":"Wegener-Panzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.03.001","article-title":"Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system","volume":"270","author":"Tanaka","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J Neurochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuron.2006.03.026","article-title":"NMDA receptors, glial cells, and clinical medicine","volume":"50","author":"Lipton","year":"2006","journal-title":"Neuron."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102611","DOI":"10.1016\/j.msard.2020.102611","article-title":"Anti-NMDAR encephalitis may develop concurrently with anti-MOG antibody-associated bilateral medial frontal cerebral cortical encephalitis and relapse with elevated CSF IL-6 and CXCL13","volume":"47","author":"Fujimori","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3389\/fneur.2019.00906","article-title":"Pediatric autoimmune encephalitis: case series from two Chinese tertiary pediatric neurology centers","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2018.12.001","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.msard.2020.102018","article-title":"Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children","volume":"42","author":"Hou","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1352458520951046","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","author":"Kunchok","year":"2020","journal-title":"Mult Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2018.03.019","article-title":"An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis","volume":"320","author":"Zhou","year":"2018","journal-title":"J Neuroimmunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.12.017","article-title":"A rare concurrence: antibodies against myelin oligodendrocyte glycoprotein and N-methyl-d-aspartate receptor in a child","volume":"28","author":"Sarigecili","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jneuroim.2018.12.003","article-title":"A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: different biological evolution of the two associated antibodies","volume":"328","author":"Rojc","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"577124","DOI":"10.1016\/j.jneuroim.2019.577124","article-title":"Overlapping autoimmune syndrome: a case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease","volume":"339","author":"P\u00e9rez","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e21238","DOI":"10.1097\/MD.0000000000021238","article-title":"Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: a retrospective observational study","volume":"99","author":"Du","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e24234","DOI":"10.1097\/MD.0000000000024234","article-title":"Clinical analysis of a patient simultaneously positive for antibodies of myelin oligodendrocyte glycoprotein and anti-N-methyl-D-aspartate receptor: a case report","volume":"100","author":"Cao","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102468","DOI":"10.1016\/j.msard.2020.102468","article-title":"Coexistent MOG, NMDAR, CASPR2 antibody positivity: triumph over the triumvirate","volume":"46","author":"Cherian","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.msard.2019.08.002","article-title":"Repeated anti-N-methyl-D-aspartate receptor encephalitis coexisting with anti-myelin oligodendrocyte glycoprotein antibody-associated diseases: a case report","volume":"35","author":"Aoe","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s10072-020-04357-x","article-title":"Viral encephalitis followed by anti-NMDAR encephalitis with concomitant MOG antibody-positive central nervous system demyelination in a child","volume":"41","author":"Ma","year":"2020","journal-title":"Neurol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.msard.2017.09.023","article-title":"Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies","volume":"18","author":"Zhou","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100338","DOI":"10.1016\/j.ebr.2019.100338","article-title":"Overlapping demyelinating syndrome and anti-N-methyl-d-aspartate receptor encephalitis with seizures","volume":"12","author":"Taraschenko","year":"2019","journal-title":"Epilepsy Behav Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10072-020-04942-0","article-title":"Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis: a case report and review of the literature","volume":"42","author":"Nan","year":"2021","journal-title":"Neurol Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s10072-020-04343-3","article-title":"Cerebrospinal fluid MOG-antibodies in anti-NMDA receptor encephalitis with leptomeningeal enhancement","volume":"41","author":"Amano","year":"2020","journal-title":"Neurol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fneur.2019.01271","article-title":"Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: a clinical phenomenon to be taken seriously","volume":"10","author":"Ren","year":"2019","journal-title":"Front Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/ped.13053","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody neuritis optica following anti-NMDA receptor encephalitis","volume":"58","author":"Yokoyama","year":"2016","journal-title":"Pediatr Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/ana.24224","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination","volume":"76","author":"Kaneko","year":"2014","journal-title":"Ann Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","article-title":"Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis","volume":"70","author":"Kayser","year":"2013","journal-title":"JAMA Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"600169","DOI":"10.3389\/fneur.2020.600169","article-title":"Clinical and radiological features of adult onset bilateral medial frontal cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody","volume":"11","author":"Fujimori","year":"2020","journal-title":"Front Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/00207454.2020.1720676","article-title":"Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders","volume":"130","author":"Tao","year":"2020","journal-title":"Int J Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of relapses in anti-NMDAR encephalitis","volume":"77","author":"Gabilondo","year":"2011","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.711376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T21:19:54Z","timestamp":1630099194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.711376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":47,"alternative-id":["10.3389\/fneur.2021.711376"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.711376","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"article-number":"711376"}}